Section of Hematology / Oncology
Associate Professor of Medicine
Referring Physician Access Line: 1-877-DOM-2730
|BA||1997||Princeton University||Molecular Biology
|MD||2001||Emory University, School of Medicine||Medicine
|Residency||2004||The University of Chicago Medical Center||Internal Medicine
|Fellowship||2007||The University of Chicago Medical Center||Hematology/Oncology
Dr. Hahn specializes in adult hematology/oncology focusing on the treatment of breast and genitourinary malignancies. She is an Executive Officer for the National Cancer Institute-funded oncology research organization, the Cancer and Leukemia Group B and in this role oversees the development of national clinical trials in breast, respiratory, and genitourinary malignancies.
Breast cancer, Renal Cancer, Bladder Cancer, Prostate Cancer, and Testicular Cancer
- Hahn O and Salgia R, Novel Therapies for Lung Cancer, Hematology Oncology Clinics of North America, 2005:19:2:343-368.
- Hahn O, Stadler WM. Sorafenib, Curr Opin Oncol. 2006 Nov;18(6):615-21.
- Hahn O and Salgia R, Non-Receptor Tyrosine Kinase Inhibitors in Lung Cancer, Current Medicinal Chemistry, Anticancer Agents Med Chem 2007 Nov;7(6):633-42.
- O Hahn, C Yang, M Medved, G Karczmar, E Krisner, T Karrison, B Manchen, M Mitchell, M Ratain, W Stadler. Dynamic contrast enhanced MRI: a pharmacodynamic study of sorafenib in metastatic renal cell carcinoma: results of randomized, phase II trial. J Clin Oncol. 2008 Oct 1;26(28):4572-8.